2337 GMT - Breathing device maker Fisher & Paykel Healthcare's shares rise 2.5% to claw back some of Monday's steep fall, helped by President Trump agreeing to a monthlong delay to a levy on imports from Mexico. In a note, analyst Matt Montgomerie thinks the tariff threat shouldn't have a material impact on F&P Healthcare's valuation at this stage because the tariffs may ultimately be reversed or revised. Also, F&P Healthcare can shift production back to New Zealand and use Mexico as a hub for other markets. "The latter would take time to implement, but over the long term there shouldn't be a material change in F&P Healthcare's gross margin outlook," Forsyth Barr says. "This is confirmed by F&P Healthcare still expecting to reach its 65% target, albeit two to three years later than its original FY 2027/FY 2028 expectations." (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
February 03, 2025 18:37 ET (23:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.